Bristol Myers Squibb Reports 3-Year RELATIVITY-047 Data for Opdualag in Melanoma

Bristol Myers Squibb today announced 3-year follow-up data from the Phase 2/3 RELATIVITY-047 trial evaluating nivolumab plus relatlimab (Opdualag) versus nivolumab alone in patients with previously untreated advanced melanoma. At 3 years, 34.2% of patients treated with Opdualag were progression-free versus 22.4% in the nivolumab arm. These long-term data demonstrate the sustained benefit of dual LAG-3 and PD-1 blockade in melanoma and reinforce Opdualag as a standard of care in first-line advanced melanoma.